𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Trisomy 6 in a CML patient receiving imatinib mesylate therapy

✍ Scribed by Zámečníkova Adriana; Al Bahar Soad; Ramesh Pandita


Publisher
Elsevier Science
Year
2008
Tongue
English
Weight
289 KB
Volume
32
Category
Article
ISSN
0145-2126

No coin nor oath required. For personal study only.

✦ Synopsis


The emergence of chromosome abnormalities in Philadelphia-negative cells in chronic myelogenous leukemia patients during imatinib therapy have been described by several authors. While these abnormalities are frequently transient, in rare instances they may be presented on repeated occasions suggesting the possibility of the development of a new malignant clone. We describe a patient with Philadelphia chromosome-positive chronic myelogenous leukemia diagnosed in 1998, in whom multiple clonal abnormalities were identified in Ph-negative cells while on imatinib therapy. The patient developed lymphoid blast crisis associated with an additional Ph chromosome and trisomy 6 in Ph-negative cells. Our results further reinforce the importance of serial chromosomal studies in patients receiving new therapies which may ultimately lead to alternative therapies.


📜 SIMILAR VOLUMES


Myelodysplastic syndrome appearing durin
✍ Vincenzo Pitini; Carmela Arrigo; Maria Grazia Sauta; Giuseppe Altavilla 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 924 KB

The introduction of imatinib has been a major advance in the treatment of gastrointestinal stromal tumor (GIST). However, despite its remarkable efficacy and toxicity profile little is known about the potential for long-term toxicity. This may be an important issue because some patients (pts) with c

Imatinib mesylate therapy in chronic mye
✍ Giuliana Alimena; Massimo Breccia; Luigia Luciano; Fabrizio Quarantelli; Daniela 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 205 KB

To determine the impact on minimal residual disease by switching to imatinib chronic phase chronic myeloid leukaemia (CP-CML) patients responsive to interferon-alpha (IFNalpha), in stable complete cytogenetic response (CCR) but with persistent PCR positivity. Twenty-six Philadelphia positive (Ph+) C